Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – propyltiouracil

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Propyltiouracil Testmiljö

Propyltiouracil

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Bliddal S, Rasmussen AK, Sundberg K, Brocks V, Feldt-Rasmussen U. Antithyroid drug-induced fetal goitrous hypothyroidism. Nat Rev Endocrinol. 2011;7(7):396-406.

  2. Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab. 1997;82:3633-6.

  3. Grüner C, Kollert A, Wildt L, Dörr HG, Beinder E, Lang N. Intrauterine treatment of fetal goitrous hypothyroidism controlled by determination of thyroid-stimulating hormone in fetal serum A case report and review of the literature. Fetal Diagn Ther.2001;16:47-51.

  4. HAWE P, FRANCIS HH. Pregnancy and thyrotoxicosis. Br Med J. 1962;2:817-22.

  5. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1:238-49.

  6. Andersen SL, Lönn S, Vestergaard P, Törring O. Birth defects after use of antithyroid drugs in early pregnancy: a Swedish nationwide study. Eur J Endocrinol. 2017;177:369-378.

  7. Li H, Zheng J, Luo J, Zeng R, Feng N, Zhu N et al. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PLoS One. 2015;10:e0126610.

  8. Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K et al. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396-403.

  9. Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98:4373-81.

  10. Laurberg P, Andersen SL. Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk?. Eur J Endocrinol. 2014;171:R13-20.

  11. Barbero P, Ricagni C, Mercado G, Bronberg R, Torrado M. Choanal atresia associated with prenatal methimazole exposure: three new patients. Am J Med Genet A 2004;129:83-6.

  12. Ferraris S, Valenzise M, Lerone M, Divizia MT, Rosaia L, Blaid D, Nemelka O, Ferrero GB, Silengo M. Malformations following methimazole exposure in utero: An open issue. Birth Defects Research Part A 2003;67:989-92.

  13. Clementi M, Di Gianantonio E, Pelo E et al. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet 1999;83:43-6.

  14. Di Gianantonio E, Schaefer C, Mastroiacovo P, Cournot MP, Benedicenti F, Reuvers M et al. Adverse effects of prenatal methimazole exposure. Teratology 2001;64:262-6.

  15. Seo GH, Kim TH, Chung JH. Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. Ann Intern Med. 2018;6(168):405-413.

  16. Song R, Lin H, Chen Y, Zhang X, Feng W. Effects of methimazole and propylthiouracil exposure during pregnancy on the risk of neonatal congenital malformations: A meta-analysis. PLoS One. 2017;12(7):e0180108.

  17. Agrawal M, Lewis S, Premawardhana L, Dayan CM, Taylor PN, Okosieme OE. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021.

  18. Morales DR, Fonkwen L, Nordeng HME. Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta-analysis of observational studies with methodological considerations. Br J Clin Pharmacol. 2021;87(10):3890-3900.

  1. Bliddal S, Rasmussen AK, Sundberg K, Brocks V, Feldt-Rasmussen U. Antithyroid drug-induced fetal goitrous hypothyroidism. Nat Rev Endocrinol. 2011;7(7):396-406.
  2. Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab. 1997;82:3633-6.
  3. Grüner C, Kollert A, Wildt L, Dörr HG, Beinder E, Lang N. Intrauterine treatment of fetal goitrous hypothyroidism controlled by determination of thyroid-stimulating hormone in fetal serum A case report and review of the literature. Fetal Diagn Ther.2001;16:47-51.
  4. HAWE P, FRANCIS HH. Pregnancy and thyrotoxicosis. Br Med J. 1962;2:817-22.
  5. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1:238-49.
  6. Andersen SL, Lönn S, Vestergaard P, Törring O. Birth defects after use of antithyroid drugs in early pregnancy: a Swedish nationwide study. Eur J Endocrinol. 2017;177:369-378.
  7. Li H, Zheng J, Luo J, Zeng R, Feng N, Zhu N et al. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PLoS One. 2015;10:e0126610.
  8. Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K et al. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396-403.
  9. Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98:4373-81.
  10. Laurberg P, Andersen SL. Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk?. Eur J Endocrinol. 2014;171:R13-20.
  11. Barbero P, Ricagni C, Mercado G, Bronberg R, Torrado M. Choanal atresia associated with prenatal methimazole exposure: three new patients. Am J Med Genet A 2004;129:83-6.
  12. Ferraris S, Valenzise M, Lerone M, Divizia MT, Rosaia L, Blaid D, Nemelka O, Ferrero GB, Silengo M. Malformations following methimazole exposure in utero: An open issue. Birth Defects Research Part A 2003;67:989-92.
  13. Clementi M, Di Gianantonio E, Pelo E et al. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet 1999;83:43-6.
  14. Di Gianantonio E, Schaefer C, Mastroiacovo P, Cournot MP, Benedicenti F, Reuvers M et al. Adverse effects of prenatal methimazole exposure. Teratology 2001;64:262-6.
  15. Seo GH, Kim TH, Chung JH. Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. Ann Intern Med. 2018;6(168):405-413.
  16. Song R, Lin H, Chen Y, Zhang X, Feng W. Effects of methimazole and propylthiouracil exposure during pregnancy on the risk of neonatal congenital malformations: A meta-analysis. PLoS One. 2017;12(7):e0180108.
  17. Agrawal M, Lewis S, Premawardhana L, Dayan CM, Taylor PN, Okosieme OE. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021.
  18. Morales DR, Fonkwen L, Nordeng HME. Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta-analysis of observational studies with methodological considerations. Br J Clin Pharmacol. 2021;87(10):3890-3900.